Michael Gilman
Directeur/Bestuurslid bij SCHOLAR ROCK HOLDING CORPORATION
Vermogen: 522 928 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Edward Myles | M | 52 |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 6 jaar |
| Erin Moore | F | 49 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 6 jaar |
| Akshay Vaishnaw | M | 61 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 13 jaar |
| David Hallal | M | 57 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 10 jaar |
| Richard Brudnick | M | 67 |
Massachusetts Institute of Technology
| 22 jaar |
| Peter Barrett | M | 71 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Amir Nashat | M | 51 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 12 jaar |
| Jay Backstrom | M | 69 | 2 jaar | |
| Jeffrey Flier | M | 76 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 8 jaar |
| Kristina Burow | F | 50 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 10 jaar |
| Allan Seymour Bufferd | - | - |
Massachusetts Institute of Technology
| 52 jaar |
| Kerri Mowen | M | - |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 jaar |
| Jennifer C. Petter | M | - |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | 9 jaar |
| Maria Fardis | M | 56 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 3 jaar |
| Jun Lin Ho | F | 45 | 6 jaar | |
| Michael Hencke | M | - | 12 jaar | |
| Katie Peng | F | - | - | |
| Srini Akkaraju Akkaraju | M | 56 | 2 jaar | |
| Joshua Reed | M | 51 | 3 jaar | |
| Todd A. Huffman | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | 10 jaar |
| Susan Alexander | F | 67 | 21 jaar | |
| Raj Bhikhu Parekh | M | 63 |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | 9 jaar |
| Rushmie Nofsinger | F | - | 3 jaar | |
| Tom Wandless | M | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Chris Klebanoff | M | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Melanie Call | F | - |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Amanda Hargrove | F | - |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | - |
| Mohammed Qatanani | M | 50 | 2 jaar | |
| Tracey Sacco | F | 47 | 1 jaar | |
| Aric Orbach | M | - |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 2 jaar |
| Harry Raftopoulos | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
| Steve Hitchcock | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
| Carolyn Ng | M | 40 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 7 jaar |
| Heidi Hagen | F | 55 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | - |
| Keren Kocshitzki | F | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 6 jaar |
| Lior Teitelbaum | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 5 jaar |
| Zeev Zehavi | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | 11 jaar |
| Anders Götzsche | M | 56 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 4 jaar |
| Bernhard Kirschbaum | M | 65 |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
| David Grainger | M | 58 |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Thomas L. Neff | M | - |
Massachusetts Institute of Technology
| 49 jaar |
| Michael Gladstone | M | 37 |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Caryn Parlavecchio | F | 52 | 3 jaar | |
| Colleen Cuffaro | M | - |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | - |
| Matthew Norkunas | M | 46 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 1 jaar |
| Jing Marantz | M | 59 | 2 jaar | |
| Bruce B. Darling | M | 71 |
University of California, Berkeley
| 44 jaar |
| Marian Nakada | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Paul Thompson | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| Rab Prinjha | M | - |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | - |
| John Isaac | M | - |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Nagesh Mahanthappa | M | 59 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 10 jaar |
| Tony Kingsley | M | 60 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 1 jaar |
| Timothy Springer | M | 76 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | 7 jaar |
| Alan Walts | M | 64 |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | 6 jaar |
| Paula Ragan | M | 54 |
X4 Pharmaceuticals, Inc. /Old/
X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | - |
| Qing Huang | M | 62 |
University of California, Berkeley
| 6 jaar |
| Adnan Akant | M | - |
Massachusetts Institute of Technology
| 5 jaar |
| Louis S. Metzger | M | - |
Massachusetts Institute of Technology
| 10 jaar |
| Poh Kam Wong | M | 72 |
Massachusetts Institute of Technology
| 9 jaar |
| Irving Mintzer | M | - |
University of California, Berkeley
| 13 jaar |
| Greg L. Zacharias | M | - |
Massachusetts Institute of Technology
| 3 jaar |
| Sung Su Han | M | 72 |
University of California, Berkeley
| 12 jaar |
| Roger McCarthy | M | 75 |
Massachusetts Institute of Technology
| 5 jaar |
| William Young | M | 79 | 11 jaar | |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 7 jaar |
| Wei-Tek Tsai | M | 64 |
University of California, Berkeley
Massachusetts Institute of Technology
| 10 jaar |
| Paul Wotton | M | 63 |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | 3 jaar |
| Steven C. Webster | M | 67 |
Massachusetts Institute of Technology
| 5 jaar |
| Henry Hoppe | M | - |
Massachusetts Institute of Technology
| 7 jaar |
| Tami S. Smason | F | - |
University of California, Berkeley
| 8 jaar |
| Steve Brown | M | - |
Massachusetts Institute of Technology
| 5 jaar |
| Mark Gus Alexandridis | M | 66 |
Massachusetts Institute of Technology
| 6 jaar |
| Peter Carson | M | - |
University of California, Berkeley
| 8 jaar |
| Ruben Ojeda | M | - |
Massachusetts Institute of Technology
| 6 jaar |
| Gilmore O’Neill | M | 59 | 15 jaar | |
| Wai Cheung Tong | M | 70 |
University of California, Berkeley
| 3 jaar |
| Douglas Kerr | M | 57 | 2 jaar | |
| Ibrahim Hasan | M | 71 |
Massachusetts Institute of Technology
University of California, Berkeley
| 8 jaar |
| Ori Sasson | M | - |
University of California, Berkeley
| 6 jaar |
| Montgomery Alger | M | 67 |
Massachusetts Institute of Technology
| 5 jaar |
| Beth A. Marcus | M | - |
Massachusetts Institute of Technology
| 5 jaar |
| Bob Goodof | M | - |
Massachusetts Institute of Technology
| 5 jaar |
| J. Wargo | M | 69 |
Massachusetts Institute of Technology
| 6 jaar |
| Bahram Nour-Omid | M | - |
University of California, Berkeley
| 4 jaar |
| Fu Chieh Hsu | M | - |
University of California, Berkeley
| 3 jaar |
| Craig Eric Schneier | M | 76 | 8 jaar | |
| James Hildebrand Roberts | M | 67 |
University of California, Berkeley
| 5 jaar |
| Laurie A. Allen | F | 63 | 9 jaar | |
| Ethan E. Jacks | M | 70 |
Massachusetts Institute of Technology
| 5 jaar |
| Grant Norman Smith | M | 72 |
Massachusetts Institute of Technology
| 5 jaar |
| Michael J. Estrada | M | - |
University of California, Berkeley
| 3 jaar |
| Weijian Shan | M | 70 |
University of California, Berkeley
| 4 jaar |
| George Economou | M | 71 |
Massachusetts Institute of Technology
| 5 jaar |
| Robert A. Hamm | M | 72 | 7 jaar | |
| Brian E. Foody | M | - |
Massachusetts Institute of Technology
| 5 jaar |
| Michael Perlmutter | M | 73 |
Massachusetts Institute of Technology
| 6 jaar |
| Jackie W. Hoffmann | F | - |
University of California, Berkeley
| 6 jaar |
| Paul Clancy | M | 62 | 16 jaar | |
| Zaurie Zimmerman | F | - |
Massachusetts Institute of Technology
| 6 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 92 | 92.00% |
| Israël | 8 | 8.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael Gilman
- Persoonlijk netwerk